[{"id":"f4760edc-575b-4a03-b52a-92d92e44dfde","acronym":"","url":"https://clinicaltrials.gov/study/NCT02371135","created_at":"2021-01-18T11:17:42.064Z","updated_at":"2025-02-25T16:51:29.235Z","phase":"","brief_title":"Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes","source_id_and_acronym":"NCT02371135","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-04"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"7e48b936-3805-41f8-8a0b-097880eb98b4","acronym":"CEIL","url":"https://clinicaltrials.gov/study/NCT05959356","created_at":"2023-07-27T18:08:40.272Z","updated_at":"2024-07-02T16:35:13.375Z","phase":"Phase 2","brief_title":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05959356 - CEIL","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR • HER-2 • KRAS • BRAF • NRAS • SMAD4","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • BRAF wild-type • SMAD4 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • NRAS • SMAD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • BRAF wild-type • SMAD4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 11/09/2023","start_date":" 11/09/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-21"},{"id":"a20d813c-0be4-46f6-9eac-b9a7b8cfecb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05187767","created_at":"2022-01-12T15:53:45.698Z","updated_at":"2024-07-02T16:36:00.723Z","phase":"","brief_title":"Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs","source_id_and_acronym":"NCT05187767","lead_sponsor":"University of Roma La Sapienza","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-11-08"},{"id":"8a3e53ec-e4a6-4757-8002-53a0b9286f63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04306861","created_at":"2021-01-18T20:53:05.515Z","updated_at":"2024-07-02T16:36:06.945Z","phase":"","brief_title":"Novel MRI Techniques for Pancreatic Cancer","source_id_and_acronym":"NCT04306861","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" SMAD4","pipe":"","alterations":" ","tags":["SMAD4"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/09/2020","start_date":" 03/09/2020","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 08/30/2022","study_completion_date":" 08/30/2022","last_update_posted":"2022-07-21"},{"id":"f70ef90a-fdc9-405b-b396-50a810ed6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05273099","created_at":"2022-03-10T14:58:06.191Z","updated_at":"2024-07-02T16:36:13.173Z","phase":"","brief_title":"Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma","source_id_and_acronym":"NCT05273099","lead_sponsor":"Università degli Studi di Ferrara","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A","pipe":" | ","alterations":" JAK3 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-12"},{"id":"8d12d438-d87a-485c-b4b4-2495d92991e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04759261","created_at":"2021-02-18T23:55:24.048Z","updated_at":"2024-07-02T16:36:34.434Z","phase":"","brief_title":"SMAD4 Methylation and Expression Levels in Non-melanocytic Skin Cancers; SMAD4 Protein Positivity","source_id_and_acronym":"NCT04759261","lead_sponsor":"Trakya University","biomarkers":" SMAD4","pipe":"","alterations":" ","tags":["SMAD4"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2021-02-18"},{"id":"2333fc8d-28f2-4288-aae2-5611bad53f1d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01560949","created_at":"2021-01-18T06:36:46.022Z","updated_at":"2024-07-02T16:36:42.183Z","phase":"Phase 2","brief_title":"Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT01560949","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SMAD4","pipe":" | ","alterations":" SMAD4 positive","tags":["SMAD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMAD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 06/14/2012","start_date":" 06/14/2012","primary_txt":" Primary completion: 02/20/2019","primary_completion_date":" 02/20/2019","study_txt":" Completion: 02/20/2019","study_completion_date":" 02/20/2019","last_update_posted":"2020-08-10"},{"id":"e561282a-18ae-455e-bea2-17d7fe3c9439","acronym":"PANEL","url":"https://clinicaltrials.gov/study/NCT02664389","created_at":"2021-01-18T12:59:11.654Z","updated_at":"2024-07-02T16:36:43.730Z","phase":"","brief_title":"Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation","source_id_and_acronym":"NCT02664389 - PANEL","lead_sponsor":"University Hospital, Rouen","biomarkers":" TP53 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • BMPR1A","pipe":"","alterations":" ","tags":["TP53 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • BMPR1A"],"overall_status":"Completed","enrollment":" Enrollment 289","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 03/15/2017","primary_completion_date":" 03/15/2017","study_txt":" Completion: 03/15/2017","study_completion_date":" 03/15/2017","last_update_posted":"2020-06-30"}]